Avivagen’s OxC-beta™ Livestock product May Prevent Future Outbreaks Like The Wuhan Coronavirus

The emerging crisis of the Wuhan coronavirus in China has global implications with over 2,126 deaths worldwide and over 75,700 reported cases, that are increasing with each passing day. The virus has shaken financial markets across all over the world and has adversely affected a number of sectors such as travel and tourism, greatly impacting airlines and other industries. Chinese indices have sunk by more than double-digits over the past few days and this outbreak could cause China’s real GDP growth to shrink to below 4% from the 6% pace in the fourth quarter, with worse impact than SARS in 2003, according to Nomura’s Chief Economist, Ting Lu.

Livestock As The Origin Of The Wuhan Coronavirus

Interestingly, the Wuhan coronavirus first emerged in Wuhan, central China and ground zero for the outbreak was located within the meat and sea food markets. The Wuhan coronavirus is highly contagious in nature, spreading through minor saliva contact, such as coughing or kissing and  it has quickly spread internationally, with cases reported in Japan, Thailand, Singapore, Malaysia, India, Australia, U.S., Canada, France, and other parts of Western Europe and Asia. It belongs to the same family of viruses as SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome). The relationship to SARS and MERS is very interesting because both also trace their origins to animals. While SARS is believed to have originated from bats and civet cats and eventually spread to humans dispersing from a point within Guangdong, China, MERS is believed to have originated from camels. Apart from these diseases, some of the other dangerous viral diseases such as HIV, swine flu, and Ebola also originated from animals (great apes, pigs, and bats respectively). The development of the Wuhan coronavirus, illustrates humanity’s struggle with animal-borne pathogens.

Why Are Animal-Borne Diseases Affecting Us & How Do We Counter Them?

Most animals carry a range of pathogens, especially bacteria and viruses that can cause various diseases. These pathogens’ evolution and survival depends on finding and infecting new hosts and one of the best ways to do this to jump to other species. This is how diseases such as SARS and MERS entered the human population. The diseases spread through pathogens of animals consumed by humans. Livestock such as cows, lamb, pigs and  even seafood host the pathogens, and humans handling or eating the infected animals, eventually leads to the spread of disease. While this is not a new phenomenon, the alarming part is that the pathogens’ resilience is getting stronger due to antibiotic resistance. The simplest example of this is the fact that about 10% of infected people died during SARS epidemic in 2003 which is significantly higher than the 0.1% for a usual flu epidemic. The  best way to counter this is to improve the immunity of the livestock consumed without using antibiotics, so that they are capable of fighting and destroying the pathogens BEFORE they can enter the human body. This is where a company like Avivagen Inc. (TSXV:VIV) (OTCPK:CHEXF) (OTCPK:CHEXD), can help.

What Does Avivagen Do?

Based in Ottawa, Canada, Avivagen is focused on the development and commercialization of various products to replace antibiotics in livestock feeds. The purpose of its product is to optimize the health and growth of livestock by supporting the animal’s own health defenses. The Company offers products based on its OxC-beta™ technology, such as OxC-beta™ Livestock, an add-in for livestock feeds and Vivamune Health Chews supplements for companion animals. As of today, Avivagen has operations in Mexico and Latin America but is expanding its presence rapidly across the globe. Avivagen was formerly known as Chemaphor, Inc. and changed its name to Avivagen in May 2012. 

Avivagen – Building Animal Resistance Without Antibiotics

Modern reality is that pathogens are rapidly evolving and developing a resistance to antibiotics. This is why anima-borne pathogens are able to jump species and spread diseases like the Wuhan coronavirus. As a matter of fact, the World Health Organization (WHO) ranks antimicrobial resistance (AMR) among the 13 biggest health challenges that the world will face in this decade; antibiotic resistance, a subset of AMR is what leads to the outcomes that we see with the Wuhan coronavirus. WHO indicates that over 700,000 people die every year due to drug-resistant pathogens, including 230,000 from multidrug resistant tuberculosis. The only way to counter this is for animals to build their own immunity without relying on antibiotics. 

Avivagen’s OxC-beta™  technology is a major tool for combatting this concern. Its add-in for livestock feed is an antibiotic-free alternative that helps animals build their immune system. When administered to livestock used for human consumption such as chicken, cows, pigs, goats, and so on, these animals are able to fend off pathogens and viruses such as the Wuhan coronavirus would never reach the human race. The Company has already seen a huge demand of its OxC-beta™  Livestock in Asia with a huge tonnage being supplied periodically to the Philippines as well as other countries in the Asia-Pacific. It has tied up with 2 Philippines-based companies, INPHILCO and UNAHCO, to ensure the distribution of its products in Asia-Pacific. It is also working to finalize rights to sell OxC-beta™ Livestock directly to Universal Robina Corporation, one of the Philippines’ largest integrated livestock producers and branded consumer food and beverage producer based in Quezon City.

A Huge Potential Market For Avivagen’s OxC-beta™  Livestock

Avivagen is currently focusing its expansion on the Philippines which a fast-growing feed market, with an estimated annual feed production of 19 million metric tons for 2019. This has almost doubled from the 11.75 million metric tons level in 2016 with swine and broiler poultry dominating the commercial livestock space. The management expects new applications of OxC-beta™  to be utilized by a growing number of local partners, and as it pursues additional regulatory approvals in new jurisdictions. The Company has already secured approval for OxC-beta™ Livestock for specific applications in Taiwan, Mexico, Malaysia and the United States. This is a big step for the Company and given the Wuhan coronavirus crisis, it appears to be just a matter of time before its products are in demand in the Chinese markets as well. This could present an interesting opportunity for investors to capitalize on.

Key Takeaways

Avivagen is merely at the start of its growth story. The Philippines market, while almost the same size as Canada, is a very small portion of the overall global market. It caters to a genuine need of improving animal health and immunity in order to prevent the origination of infectious diseases like the Wuhan coronavirus among humans. After its recent private placement of $1.25 million, the stock is trading at around 67 cents a share but the market potential implies that this is much below the actual potential value of the stock. At its current levels, Avivagen appears to be a very interesting investment for long-term growth investors.


Except for the historic info introduced herein, issues mentioned on this article include forward-looking statements which can be topic to sure dangers and uncertainties that might trigger precise outcomes to vary materially from any future outcomes, efficiency or achievements expressed or implied by such statements. Salesparq, LLC which owns isn’t registered with any monetary or securities regulatory authority and doesn’t present nor claims to supply funding recommendation or suggestions to readers of this launch. Salesparq, LLC, which owns, could also be compensated for its companies within the type of cash-based compensation for the businesses it writes about. For making particular funding selections, readers ought to search their very own recommendation. Pursuant to an settlement between TraDigital IR and Salesparq, LLC, which owns, we have been employed for a interval from 2/15/2020 – 3/15/2020 to publicly disseminate details about Avivagen Inc., together with on the Website, e mail and different media together with Facebook and Twitter. We have been paid $20,000 (CASH) for & have been paid “0” shares of restricted frequent shares. We personally own zero shares of Avivagen, Inc. We don’t intend to purchase or promote further shares of Avivagen, Inc. within the open market at any time, together with earlier than, throughout or after the Website and Information, present public dissemination of favorable Information. Please learn our full disclaimer right here:


This website is a wholly owned subsidiary of Salesparq, LLC, herein referred to as Salesparq, LLC. Our publications are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. We may receive compensation for this article on a PPC basis as an affiliate. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.PLEASE NOTE WELL: Salesparq, LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.Release of Liability: Through use of this website viewing or using you agree to hold Salesparq, LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Salesparq, LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and Salesparq, LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead Salesparq, LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. Salesparq, LLC is compliant with the Can Spam Act of 2003. Salesparq, LLC does not offer such advice or analysis, and Salesparq, LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.In preparing this publication, Salesparq, LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. Salesparq, LLC has not been compensated for this article. The advertisements in this website are believed to be reliable, however, Salesparq, LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. Salesparq, LLC is not responsible for any claims made by the companies advertised herein, nor is Salesparq, LLC responsible for any other promotional firm, its program or its structure. Salesparq, LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA.
Show More

Related Articles

Back to top button